elosulfase alfa sold brand name vimizim medication used treatment morquio syndrome caused deficiency enzyme elosulfase alfa synthetic version enzyme elosulfase alfa developed biomarin pharmaceutical inc approved use us food drug administration elosulfase alfa used enzyme replacement therapy study confirmed effective young patients morquio syndrome type treatment medication effective upon respiratory symptoms activities daily living growth confirmed cost elosulfase alfa countries year made difficult health systems afford june belgian court issued preliminary injunction forcing biomarin continue supplying vimizim young girl suffering morquio syndrome free charge biomarin stopped providing drug free beginning year negotiations belgian health authorities regarding reimbursement product repeatedly failed caused parents start legal proceedings force company keep providing medicine free charge biomarin ordered keep definitive judgment would rendered medicine would available belgian market reasonable drug article relating gastrointestinal system stub help wikipedia expanding ithttpsenwikipediaorgwikielosulfasealfa